Trial NCT03601507

View at ClinicalTrials.gov 
Org. Study IDs: 1802258478
Secondary IDs: 1802258478 CBYL719XUS15T NCI-2018-00507 P30CA023074

Last trial update was posted on 2024-04-17

MeSH Interventions

Phosphoinositide-3 Kinase Inhibitors

MeSH Conditions

Carcinoma Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck

Other Conditions

CDKN2A-p16 Positive HPV Positive Oropharyngeal Squamous Cell Carcinoma Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7 Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7 Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7

Stopping Reasons

Novartis has chosen to withdraw support for this trial

Limitations And Caveats

This study stopped accrual early as the investigational product (IP) manufacturer, Novartis, terminated the study stopping provision of IP. 6 out of 20 subjects were accrued, 5 of which completed study. Due to early termination with few patients, only the counts of events have been calculated and no testing was done.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID